Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR‐TKI treatment

Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) is effective in lung cancer patients carrying sensitive EGFR mutations. In this study, we investigated if liver X receptor (LXR) agonist T0901317 could reverse the resistance of lung cancer cell lines A549 and H1650 to EGFR‐TKI tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Haixia, Yu, Shaorong, Chen, Dan, Jing, Changwen, Wang, Zhuo, Ma, Rong, Liu, Siwen, Ni, Jie, Feng, Jifeng, Wu, Jianzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221460/
https://www.ncbi.nlm.nih.gov/pubmed/28097086
http://dx.doi.org/10.1002/2211-5463.12147
_version_ 1782492816826433536
author Cao, Haixia
Yu, Shaorong
Chen, Dan
Jing, Changwen
Wang, Zhuo
Ma, Rong
Liu, Siwen
Ni, Jie
Feng, Jifeng
Wu, Jianzhong
author_facet Cao, Haixia
Yu, Shaorong
Chen, Dan
Jing, Changwen
Wang, Zhuo
Ma, Rong
Liu, Siwen
Ni, Jie
Feng, Jifeng
Wu, Jianzhong
author_sort Cao, Haixia
collection PubMed
description Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) is effective in lung cancer patients carrying sensitive EGFR mutations. In this study, we investigated if liver X receptor (LXR) agonist T0901317 could reverse the resistance of lung cancer cell lines A549 and H1650 to EGFR‐TKI treatment. We found that T0901317 could make natural EGFR‐TKI‐resistant A549 human lung cancer cells sensitive to EGFR‐TKI treatment and that this was dependent on LXRβ expression. However, T0901317 does not have a similar effect on another natural EGFR‐TKI‐resistant cell line H1650.
format Online
Article
Text
id pubmed-5221460
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-52214602017-01-17 Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR‐TKI treatment Cao, Haixia Yu, Shaorong Chen, Dan Jing, Changwen Wang, Zhuo Ma, Rong Liu, Siwen Ni, Jie Feng, Jifeng Wu, Jianzhong FEBS Open Bio Research Articles Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) is effective in lung cancer patients carrying sensitive EGFR mutations. In this study, we investigated if liver X receptor (LXR) agonist T0901317 could reverse the resistance of lung cancer cell lines A549 and H1650 to EGFR‐TKI treatment. We found that T0901317 could make natural EGFR‐TKI‐resistant A549 human lung cancer cells sensitive to EGFR‐TKI treatment and that this was dependent on LXRβ expression. However, T0901317 does not have a similar effect on another natural EGFR‐TKI‐resistant cell line H1650. John Wiley and Sons Inc. 2016-12-20 /pmc/articles/PMC5221460/ /pubmed/28097086 http://dx.doi.org/10.1002/2211-5463.12147 Text en © 2016 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Cao, Haixia
Yu, Shaorong
Chen, Dan
Jing, Changwen
Wang, Zhuo
Ma, Rong
Liu, Siwen
Ni, Jie
Feng, Jifeng
Wu, Jianzhong
Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR‐TKI treatment
title Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR‐TKI treatment
title_full Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR‐TKI treatment
title_fullStr Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR‐TKI treatment
title_full_unstemmed Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR‐TKI treatment
title_short Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR‐TKI treatment
title_sort liver x receptor agonist t0901317 reverses resistance of a549 human lung cancer cells to egfr‐tki treatment
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221460/
https://www.ncbi.nlm.nih.gov/pubmed/28097086
http://dx.doi.org/10.1002/2211-5463.12147
work_keys_str_mv AT caohaixia liverxreceptoragonistt0901317reversesresistanceofa549humanlungcancercellstoegfrtkitreatment
AT yushaorong liverxreceptoragonistt0901317reversesresistanceofa549humanlungcancercellstoegfrtkitreatment
AT chendan liverxreceptoragonistt0901317reversesresistanceofa549humanlungcancercellstoegfrtkitreatment
AT jingchangwen liverxreceptoragonistt0901317reversesresistanceofa549humanlungcancercellstoegfrtkitreatment
AT wangzhuo liverxreceptoragonistt0901317reversesresistanceofa549humanlungcancercellstoegfrtkitreatment
AT marong liverxreceptoragonistt0901317reversesresistanceofa549humanlungcancercellstoegfrtkitreatment
AT liusiwen liverxreceptoragonistt0901317reversesresistanceofa549humanlungcancercellstoegfrtkitreatment
AT nijie liverxreceptoragonistt0901317reversesresistanceofa549humanlungcancercellstoegfrtkitreatment
AT fengjifeng liverxreceptoragonistt0901317reversesresistanceofa549humanlungcancercellstoegfrtkitreatment
AT wujianzhong liverxreceptoragonistt0901317reversesresistanceofa549humanlungcancercellstoegfrtkitreatment

Ejemplares similares